Leman Biotech is a clinical-stage biotech company. We are a spin-off of EPFL, dedicated to develop next-generation metabolic cancer immunotherapies. Our exclusive metabolic reprogramming technology reverses T-cell exhaustion, a major bottleneck in cancer immunotherapies.

Products, services, technology

We have two products under development: the Meta10-19 CAR-T cell therapy, in clinical stage, has shown great promise in low-dose treatment for recurrent or refractory lymphoma; the IL-10/Fc protein drug, in CMC stage, has demonstrated impressive results up to 90% cure rate in preclinical studies.

Cooperation possibilities

R&D, co-development, partnering, licensing, funding.

Some insights
Additional address info
  • Building Serine
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in